fig5
![Assessment of response to liver directed radiation-based therapies: Current guidelines, challenges, and future directions](https://image.oaes.cc/2873b637-e4cb-4913-b722-470f11e30900/5378.fig.5.jpg)
Figure 5. 89-year-old male, chronic hepatitis B infection, arterial phase CT images. Pretreatment image shows a 2.3 LR-5 observation with APHE and washout (not shown), consistent with hepatocellular carcinoma (HCC). Three-month follow-up image after Y-90 shows peripheral nodular arterial phase hyperenhancement (APHE) along the treatment zone (black arrow) measuring 1.1 cm, which fulfills the criteria for residual viable tumor according to LR-Treatment response algorithm (LR-TRA) and mRECIST. On 6 and 9 months follow-up, note progressive decrease in size, consistent with tumor response (white arrows). Ill-defined APHE is still observed on the 9-month follow-up.